Oncology stories

Aug 4, 2026

Pathos AI Signs Two Major Breast Cancer Drug Licensing Deals Worth Over $2B, Plans $3B Series E

Pathos AI announced two significant licensing agreements for breast cancer treatments: a $2.2 billion deal with China's Alphamab Oncology for bispecific ADC JSKN016 targeting triple-negative breast cancer, and a co-exclusive agreement with AstraZeneca for ERα degrader AZD4241 for ER-positive breast cancer. The company is reportedly planning to raise a Series E round at a $3 billion valuation.

Aug 4, 20268 sources

Pathos AI Signs Two Major Breast Cancer Drug Licensing Deals Worth Over $2B, Plans $3B Series E

University researchers develop new human tissue model to study glioblastoma infiltration

GSK partner Hansoh Pharmaceutical's bone cancer drug meets primary endpoint in second Phase III trial in China

AstraZeneca reports mixed late-stage trial results with Ultomiris failure and Claudin 18.2 ADC success

AstraZeneca's Sonesitatug Vedotin Shows Significant Survival Improvement in Phase III Gastric Cancer Trial

FDA Approves Celcuity's Revtorpyk (Gedatolisib) for Advanced Breast Cancer

Roche's divarasib outperforms Amgen and Bristol Myers Squibb drugs in Phase 3 lung cancer trial

BeOne Medicines' Brukinsa Meets Primary Endpoint in Phase 3 Frontline Mantle Cell Lymphoma Trial

AbbVie and Genmab's Epkinly Combination Meets Primary Endpoint in Phase 3 Trial for Relapsed/Refractory DLBCL

FDA approves Trodelvy for first-line triple-negative breast cancer

China Approves World's First CAR-T Therapy for Solid Tumors to Treat Advanced Gastric Cancer

FDA Approves Belzutifan Plus Pembrolizumab as Adjuvant Therapy for Clear Cell Renal Cell Carcinoma

Moderna's personalized mRNA melanoma vaccine cuts cancer recurrence risk by half in five-year trial results

Related timelines

Iran War

US Congress

Venture capital funding

Strait of Hormuz blockage

Trump administration